A Bayesian adaptive design with biomarkers for targeted therapies

Clinical Trials

Volumn 7, Issue 5, 2010, Pages 546-556

  Eickhoff, Jens C ^a,b   Kim, Kyungmann ^a,b   Beach, Jason ^a   Kolesar, Jill M ^b   Gee, Jason R ^c,d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^d LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

BAYES THEOREM; CLINICAL STUDY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG TARGETING; EVALUATION; HUMAN; PATIENT ASSESSMENT; PATIENT IDENTIFICATION; PREDICTOR VARIABLE; PRIORITY JOURNAL; SAMPLE SIZE; SIMULATION; TREATMENT OUTCOME;

BAYES THEOREM; BIOLOGICAL MARKERS; HUMANS; LOGISTIC MODELS; MOLECULAR TARGETED THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; STATISTICS AS TOPIC; TREATMENT OUTCOME;

EID: 78649918672     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774510372657     Document Type: Conference Paper

References (27)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Therap 2001 ; 69: 89-95.
2. Bower R., Shyjian A. Biomarker World Congress. Personalized Med 2005 ; 2: 209-12.
3. Goetz MP, Ames MM, Weinshilboum RM Primer on medical genomics: Pharmacogenomics-general principles with cancer as a model. Mayo Clin Proc 2004 ; 79: 376-84.
4. Carrol K. Biomarkers in drug development. Friend or foe? Biopharmaceutical Report, 2006, pp. 3-6.
5. Mandrekar S., Grothey A., Goetz MP, Sargent DJ Clinical trial designs for prospective validation of biomarkers. Am J Pharmacogenomics 2005 ; 5: 317-25.
6. Sargent DJ, Conley BA, Allegra C., Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005 ; 23: 2020-27.
7. Maitournam A., Simon R. On the efficiency of targeted clinical trials. Stat Med 2005 ; 15: 329-39.
8. Simon R., Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 2004 ; 10: 6759-63.
9. Longley DB, Harkin DP, Johnston PG 5-Fluorouracil: mechanism of action and clinical strategies. Nat Rev Cancer 2003 ; 3: 330-38.
10. Shipp MA, Ross KN, Tamayo P., et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002 ; 8: 68-74.
11. Simon R., Radmacher MD, Dobbin K., McShane LM Pitfalls in the analysis of DNA microarray data for diagnostic and prognostic classification. J National Cancer Inst 2003 ; 95: 14-18. (Pubitemid 36124291)
12. Zelen M. Play the winner rule and the controlled clinical trial. J Am Stat Assoc 1969 ; 64: 131-46.
13. Sobel M., Weiss GH Play the winner rule and inverse sampling in selecting the better of two binomial populations. J Am Stat Assoc 1971 ; 66: 546-51.
14. Berry DA, Eick SG Adaptive assignment versus balanced randomization in clinical trials: A decision analysis. Stat Med 1995 ; 14: 231-46.
15. Muller HH, Schafer H. Adaptive group sequential designs for clinical trials: Combining the advantage of adaptive and classical group sequential approaches. Biometrics 2001 ; 57: 886-91.
16. Chow SC, Chang M., Pong A. Statistical consideration of adaptive methods in clinical development. J Biopharm Stat 2005 ; 15: 575-91.
17. Zhou X., Liu S., Kim ES, et al. Bayesian adaptive design for targeted therapy development in lung cancer a step toward personalized medicine. Clin Trials 2008 ; 5: 181-93.
18. Holmes CC, Held L. Bayesian auxiliary variable models for binary and multinomial regression. Bayesian Anal 2006 ; 1: 145-68.
19. Devroye L. Non-uniform Random Variate Generations. Springer, New York, 1986.
20. Robert CP, Casella G. Monte Carlo Statistical Methods (2nd edn). Springer-Verlag, New York, 2004.
21. Rosenberger WF, Flournoy N., Durham SD Asymptotic normality of maximum likelihood estimators from multiparameter response-driven designs. J Stat Plan Inference 1997 ; 60: 69-76.
22. Rosenberger WF, Vidyashankar AN, Agarwal DK Covariate-adjusted response-adaptive designs for binary response. J Biopharm Stat 2002 ; 11: 227-36.
23. Zhang LX, Hu F. A new family of covariate-adjusted response adaptive designs and their properties. Appl Math J 2009 ; 24: 1-13.
24. Thall PF, Wathen JK Practical Bayesian adaptive randomization in clinical trials. Eur J Cancer 2007 ; 43: 859-66.
25. Garthwaite PH An interpretation of partial least squares. J Am Stat Assoc 1994 ; 89: 122-27.
26. Nguyen D., Rocke D. Tumor classifications by partial least squares using microarray gene expression data. Bioinformatics 2002 ; 18: 39-50.
27. Bastien P., Vinzi VE, Tenenhaus M. PLS genearlized linear regression. Comput Stat Data Analysis 2005 ; 48: 17-46.